JP2018524349A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524349A5 JP2018524349A5 JP2017568261A JP2017568261A JP2018524349A5 JP 2018524349 A5 JP2018524349 A5 JP 2018524349A5 JP 2017568261 A JP2017568261 A JP 2017568261A JP 2017568261 A JP2017568261 A JP 2017568261A JP 2018524349 A5 JP2018524349 A5 JP 2018524349A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 114
- 239000000427 antigen Substances 0.000 claims description 113
- 102000036639 antigens Human genes 0.000 claims description 113
- 108091007433 antigens Proteins 0.000 claims description 113
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 94
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 52
- 229920001184 polypeptide Polymers 0.000 claims description 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 32
- 125000000539 amino acid group Chemical group 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 26
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 21
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims description 20
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims description 20
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims description 20
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims description 20
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims description 20
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims description 20
- 150000001768 cations Chemical class 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 125000003010 ionic group Chemical group 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims description 12
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims description 12
- 150000001412 amines Chemical class 0.000 claims description 12
- 235000001014 amino acid Nutrition 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 102000052088 human IL3RA Human genes 0.000 claims description 10
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 9
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 9
- 125000003172 aldehyde group Chemical group 0.000 claims description 9
- 229940127121 immunoconjugate Drugs 0.000 claims description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 7
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical group NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 5
- 230000003647 oxidation Effects 0.000 claims description 5
- 238000007254 oxidation reaction Methods 0.000 claims description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 4
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 102000006395 Globulins Human genes 0.000 claims description 2
- 108010044091 Globulins Proteins 0.000 claims description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 210000004748 cultured cell Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000002649 immunization Methods 0.000 claims description 2
- 230000003053 immunization Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 22
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 11
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 6
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 3
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 208000016778 CD4+/CD56+ hematodermic neoplasm Diseases 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 description 42
- 108010056243 alanylalanine Proteins 0.000 description 24
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 24
- LIWMQSWFLXEGMA-WDSKDSINSA-N Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)N LIWMQSWFLXEGMA-WDSKDSINSA-N 0.000 description 12
- 0 COc(cc(c(NC[C@](C1)N2c3c1cccc3)c1)C2=O)c1OCc1cc(COc(cc(c2c3)C(*)=C=C(*)[C@](Cc4ccccc44)N4C2=O)c3OC)cc(**SS)c1 Chemical compound COc(cc(c(NC[C@](C1)N2c3c1cccc3)c1)C2=O)c1OCc1cc(COc(cc(c2c3)C(*)=C=C(*)[C@](Cc4ccccc44)N4C2=O)c3OC)cc(**SS)c1 0.000 description 12
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 12
- DEFJQIDDEAULHB-QWWZWVQMSA-N D-alanyl-D-alanine Chemical compound C[C@@H]([NH3+])C(=O)N[C@H](C)C([O-])=O DEFJQIDDEAULHB-QWWZWVQMSA-N 0.000 description 12
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 12
- DEFJQIDDEAULHB-UHFFFAOYSA-N N-D-alanyl-D-alanine Natural products CC(N)C(=O)NC(C)C(O)=O DEFJQIDDEAULHB-UHFFFAOYSA-N 0.000 description 12
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 12
- 241000282567 Macaca fascicularis Species 0.000 description 8
- KQRHTCDQWJLLME-XUXIUFHCSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N KQRHTCDQWJLLME-XUXIUFHCSA-N 0.000 description 6
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 description 6
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 description 6
- RVLOMLVNNBWRSR-KNIFDHDWSA-N (2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O RVLOMLVNNBWRSR-KNIFDHDWSA-N 0.000 description 6
- WEZDRVHTDXTVLT-GJZGRUSLSA-N 2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 WEZDRVHTDXTVLT-GJZGRUSLSA-N 0.000 description 6
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 6
- DAQIJMOLTMGJLO-YUMQZZPRSA-N Arg-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N DAQIJMOLTMGJLO-YUMQZZPRSA-N 0.000 description 6
- -1 D-Phe-Phe-Lys Chemical compound 0.000 description 6
- 108010009504 Gly-Phe-Leu-Gly Proteins 0.000 description 6
- YLEIWGJJBFBFHC-KBPBESRZSA-N Gly-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 YLEIWGJJBFBFHC-KBPBESRZSA-N 0.000 description 6
- VAXBXNPRXPHGHG-BJDJZHNGSA-N Ile-Ala-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)O)N VAXBXNPRXPHGHG-BJDJZHNGSA-N 0.000 description 6
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 6
- LSPYFSHXDAYVDI-SRVKXCTJSA-N Leu-Ala-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(C)C LSPYFSHXDAYVDI-SRVKXCTJSA-N 0.000 description 6
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 description 6
- JHKXZYLNVJRAAJ-WDSKDSINSA-N Met-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(O)=O JHKXZYLNVJRAAJ-WDSKDSINSA-N 0.000 description 6
- MIDZLCFIAINOQN-WPRPVWTQSA-N Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 MIDZLCFIAINOQN-WPRPVWTQSA-N 0.000 description 6
- RBRNEFJTEHPDSL-ACRUOGEOSA-N Phe-Phe-Lys Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 RBRNEFJTEHPDSL-ACRUOGEOSA-N 0.000 description 6
- HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 description 6
- QRZVUAAKNRHEOP-GUBZILKMSA-N Val-Ala-Val Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O QRZVUAAKNRHEOP-GUBZILKMSA-N 0.000 description 6
- IBIDRSSEHFLGSD-YUMQZZPRSA-N Val-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-YUMQZZPRSA-N 0.000 description 6
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 description 6
- 108010054982 alanyl-leucyl-alanyl-leucine Proteins 0.000 description 6
- 108010068380 arginylarginine Proteins 0.000 description 6
- 108010036533 arginylvaline Proteins 0.000 description 6
- 108010054155 lysyllysine Proteins 0.000 description 6
- 108010024607 phenylalanylalanine Proteins 0.000 description 6
- IBIDRSSEHFLGSD-UHFFFAOYSA-N valinyl-arginine Natural products CC(C)C(N)C(=O)NC(C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-UHFFFAOYSA-N 0.000 description 6
- 108010073969 valyllysine Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- SZVNORTXUATKNF-HWKANZROSA-N C/C=N/NC(C)=O Chemical compound C/C=N/NC(C)=O SZVNORTXUATKNF-HWKANZROSA-N 0.000 description 1
- YCKRVGKVZGBWHU-UHFFFAOYSA-N CC(CC(N1CC(CC2)CCC2C(C)=O)=O)C1=O Chemical compound CC(CC(N1CC(CC2)CCC2C(C)=O)=O)C1=O YCKRVGKVZGBWHU-UHFFFAOYSA-N 0.000 description 1
- UIWVQFSAXYWENY-UHFFFAOYSA-N CCNNC(C)=O Chemical compound CCNNC(C)=O UIWVQFSAXYWENY-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022209445A JP7611218B2 (ja) | 2015-06-29 | 2022-12-27 | 抗ｃｄ１２３抗体、ならびにその複合体及び誘導体 |
| JP2024226350A JP2025041791A (ja) | 2015-06-29 | 2024-12-23 | 抗ｃｄ１２３抗体、ならびにその複合体及び誘導体 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562186161P | 2015-06-29 | 2015-06-29 | |
| US62/186,161 | 2015-06-29 | ||
| US201662338203P | 2016-05-18 | 2016-05-18 | |
| US62/338,203 | 2016-05-18 | ||
| US201662346730P | 2016-06-07 | 2016-06-07 | |
| US62/346,730 | 2016-06-07 | ||
| PCT/US2016/039797 WO2017004026A1 (en) | 2015-06-29 | 2016-06-28 | Anti-cd 123 antibodies and conjugates and derivatives thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022209445A Division JP7611218B2 (ja) | 2015-06-29 | 2022-12-27 | 抗ｃｄ１２３抗体、ならびにその複合体及び誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018524349A JP2018524349A (ja) | 2018-08-30 |
| JP2018524349A5 true JP2018524349A5 (enExample) | 2019-08-08 |
| JP7203497B2 JP7203497B2 (ja) | 2023-01-13 |
Family
ID=56373176
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568261A Active JP7203497B2 (ja) | 2015-06-29 | 2016-06-28 | 抗ｃｄ１２３抗体、ならびにその複合体及び誘導体 |
| JP2022209445A Active JP7611218B2 (ja) | 2015-06-29 | 2022-12-27 | 抗ｃｄ１２３抗体、ならびにその複合体及び誘導体 |
| JP2024226350A Pending JP2025041791A (ja) | 2015-06-29 | 2024-12-23 | 抗ｃｄ１２３抗体、ならびにその複合体及び誘導体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022209445A Active JP7611218B2 (ja) | 2015-06-29 | 2022-12-27 | 抗ｃｄ１２３抗体、ならびにその複合体及び誘導体 |
| JP2024226350A Pending JP2025041791A (ja) | 2015-06-29 | 2024-12-23 | 抗ｃｄ１２３抗体、ならびにその複合体及び誘導体 |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US10077313B2 (enExample) |
| EP (2) | EP3313884B9 (enExample) |
| JP (3) | JP7203497B2 (enExample) |
| KR (2) | KR102663480B1 (enExample) |
| CN (4) | CN107889493B (enExample) |
| AR (1) | AR105194A1 (enExample) |
| AU (2) | AU2016285552B2 (enExample) |
| BR (1) | BR112017027254A2 (enExample) |
| CA (1) | CA2989321A1 (enExample) |
| CY (1) | CY1123884T1 (enExample) |
| DK (1) | DK3313884T3 (enExample) |
| ES (1) | ES2887273T3 (enExample) |
| HR (1) | HRP20210263T1 (enExample) |
| HU (1) | HUE053619T2 (enExample) |
| IL (2) | IL256271B (enExample) |
| LT (1) | LT3313884T (enExample) |
| MD (1) | MD3313884T2 (enExample) |
| PL (1) | PL3313884T3 (enExample) |
| PT (1) | PT3313884T (enExample) |
| RS (1) | RS61452B9 (enExample) |
| RU (1) | RU2739612C2 (enExample) |
| SG (1) | SG10202005144TA (enExample) |
| SI (1) | SI3313884T1 (enExample) |
| SM (1) | SMT202100092T1 (enExample) |
| TW (3) | TW202423981A (enExample) |
| WO (1) | WO2017004026A1 (enExample) |
| ZA (1) | ZA202007918B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10206942B2 (en) | 2015-04-10 | 2019-02-19 | Thomas Jefferson University | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes |
| RU2733740C2 (ru) | 2015-06-29 | 2020-10-06 | Иммуноджен, Инк. | Конъюгаты сконструированных антител с цистеиновыми заменами |
| BR112017027254A2 (pt) | 2015-06-29 | 2019-05-14 | Immunogen, Inc. | anticorpos anti-cd123 e conjugados e derivados dos mesmos |
| DK3380525T3 (da) | 2015-11-25 | 2024-01-29 | Immunogen Inc | Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf |
| TWI845890B (zh) | 2016-11-23 | 2024-06-21 | 美商伊繆諾金公司 | 苯二氮平衍生物之選擇性磺化 |
| TW201825515A (zh) * | 2017-01-04 | 2018-07-16 | 美商伊繆諾金公司 | Ｍｅｔ抗體以及其免疫結合物及用途 |
| AU2018213202B2 (en) * | 2017-01-25 | 2022-03-24 | Immunogen, Inc. | Methods of preparing cytotoxic benzodiazepine derivatives |
| AU2018229277B2 (en) | 2017-02-28 | 2025-03-20 | Immunogen, Inc. | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof |
| EP4374850A2 (en) | 2017-09-22 | 2024-05-29 | ImmunoGen, Inc. | Methods of preventing methionine oxidation in immunoconjugates |
| TWI826393B (zh) | 2017-09-22 | 2023-12-21 | 美商免疫遺傳股份有限公司 | 使用陽離子交換層析法分離三輕鏈抗體 |
| IL301638B2 (en) | 2017-09-29 | 2024-09-01 | Daiichi Sankyo Co Ltd | Antibody-pyrrolobenzodiazepine derivative conjugate |
| PE20201255A1 (es) * | 2017-10-27 | 2020-11-16 | Pfizer | Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos |
| KR20200094181A (ko) | 2017-11-29 | 2020-08-06 | 마젠타 테라퓨틱스 인코포레이티드 | Cd5+ 세포를 고갈시키기 위한 조성물 및 방법 |
| US12201154B2 (en) | 2018-01-03 | 2025-01-21 | Cqens Technologies Inc. | Heat-not-burn device and method |
| JP7474195B2 (ja) | 2018-01-12 | 2024-04-24 | イミュノジェン， インコーポレイテッド | 抗体薬物のコンジュゲーション、精製、及び製剤のための方法 |
| CN116425874A (zh) * | 2018-06-15 | 2023-07-14 | 康源博创生物科技(北京)有限公司 | 抗cd123抗体及其制备方法和应用 |
| MA54088A (fr) * | 2018-10-30 | 2022-03-16 | Immunogen Inc | Procédés de traitement faisant appel à des immunoconjugués anti-cd123 |
| WO2020092344A1 (en) * | 2018-10-31 | 2020-05-07 | Health Research, Inc. | Combination treatment with anti-cd123 antibody drug conjugate and parp inhibitor |
| CN112996792B (zh) * | 2018-11-12 | 2024-04-26 | 伊缪诺金公司 | 制备细胞毒性苯并二氮杂卓衍生物的方法 |
| SG11202104423XA (en) * | 2018-11-12 | 2021-05-28 | Immunogen Inc | Methods of preparing cytotoxic benzodiazepine derivatives |
| JP2022518150A (ja) * | 2019-01-07 | 2022-03-14 | マジェンタ セラピューティクス インコーポレイテッド | 細胞療法での抗ｃｄ４５抗体－薬物結合体（ａｄｃ）の使用経験 |
| WO2020191306A1 (en) | 2019-03-21 | 2020-09-24 | Immunogen, Inc. | Methods of preparing cell-binding agent-drug conjugates |
| CN113661172A (zh) | 2019-03-29 | 2021-11-16 | 伊缪诺金公司 | 用于抑制异常细胞生长或治疗增生性疾病的细胞毒性双苯并二氮杂䓬衍生物及其与细胞结合剂的缀合物 |
| CN113853217A (zh) * | 2019-04-29 | 2021-12-28 | 伊缪诺金公司 | 包含抗cd123免疫缀合物的治疗组合 |
| EP4028420A1 (en) * | 2019-09-13 | 2022-07-20 | Mythic Therapeutics, Inc. | Antigen-binding protein constructs and uses thereof |
| CN112646033B (zh) * | 2020-12-16 | 2022-04-12 | 北京艺妙神州医药科技有限公司 | 靶向cd123的嵌合抗原受体及其用途 |
| TW202330608A (zh) | 2021-09-30 | 2023-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 吡咯并苯并二氮雜卓類衍生物及其偶聯物、其製備方法及其應用 |
| CN120957759A (zh) * | 2023-05-12 | 2025-11-14 | 四川科伦博泰生物医药股份有限公司 | 具有抗肿瘤作用的化合物及其制备方法和用途 |
| US20250051463A1 (en) | 2023-07-31 | 2025-02-13 | Astrazeneca Ab | Cd123 antibody-drug conjugates and methods of using the same |
| US20250345449A1 (en) | 2024-05-10 | 2025-11-13 | Immunogen, Inc. | Anti-cd123 immunoconjugates for the treatment of blastic plasmacytoid cell neoplasm |
| WO2025235924A2 (en) | 2024-05-10 | 2025-11-13 | Immunogen, Inc. | Anti-cd123 immunoconjugates for the treatment of acute myeloid leukemia |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| WO1986005803A1 (fr) | 1985-03-30 | 1986-10-09 | Marc Ballivet | Procede d'obtention d'adn, arn, peptides, polypeptides ou proteines, par une technique de recombinaison d'adn |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
| CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
| FI915411A7 (fi) | 1989-05-16 | 1991-11-15 | Scripps Research Inst | Heteromeeristen reseptorien koe-ekspressio |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US7264963B1 (en) | 1995-08-18 | 2007-09-04 | Morphosys Ag | Protein(poly)peptide libraries |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| WO2001002588A2 (en) | 1999-07-02 | 2001-01-11 | Morphosys Ag | Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests |
| US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| WO2004043344A2 (en) | 2002-11-07 | 2004-05-27 | Immunogen, Inc. | Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same |
| WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
| WO2006024497A1 (en) | 2004-08-30 | 2006-03-09 | Lonza Biologics Plc. | Affinity- plus ion exchange- chromatography for purifying antibodies |
| KR101624587B1 (ko) * | 2005-12-20 | 2016-05-26 | 에스비아이 바이오테크 가부시키가이샤 | 항-ｉｌｔ7 항체 |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| WO2008127735A1 (en) * | 2007-04-13 | 2008-10-23 | Stemline Therapeutics, Inc. | Il3ralpha antibody conjugates and uses thereof |
| EP2287174B8 (en) | 2008-01-18 | 2016-12-07 | Bio-Rad Laboratories, Inc. | Enhanced purification of antibody fragments by apatite chromatography |
| JP5470817B2 (ja) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | 電池用電極およびこれを用いた電池、並びにその製造方法 |
| US20100209341A1 (en) | 2009-02-18 | 2010-08-19 | Csl Limited | Treatment of chronic inflammatory conditions |
| CN104558179A (zh) | 2009-04-27 | 2015-04-29 | 协和发酵麒麟株式会社 | 用于治疗血液肿瘤的抗IL-3Rα抗体 |
| CN102821815A (zh) | 2010-02-18 | 2012-12-12 | Csl有限公司 | 慢性炎症状态的治疗 |
| SG10201501342UA (en) | 2010-02-24 | 2015-04-29 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
| JP2013534520A (ja) | 2010-06-08 | 2013-09-05 | ジェネンテック， インコーポレイテッド | システイン操作抗体及びコンジュゲート |
| NZ604510A (en) | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
| IL279304B (en) | 2011-02-15 | 2022-07-01 | Immunogen Inc | Method for producing an indolinobenzodiazepine |
| JP6136279B2 (ja) | 2013-01-15 | 2017-05-31 | 株式会社ジェイテクト | 転がり軸受装置 |
| WO2014138805A1 (en) | 2013-03-14 | 2014-09-18 | Csl Limited | Anti il-3r alpha agents and uses thereof |
| TWI503850B (zh) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | 過電流保護元件 |
| EP2839842A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| AU2014326674B2 (en) * | 2013-09-26 | 2020-03-12 | Ablynx Nv | Bispecific nanobodies |
| TWI510996B (zh) | 2013-10-03 | 2015-12-01 | Acer Inc | 控制觸控面板的方法以及使用該方法的可攜式電腦 |
| CN106456762A (zh) * | 2014-05-20 | 2017-02-22 | 伊缪诺金公司 | 用于表征和治疗急性髓样白血病的方法 |
| PT3189056T (pt) * | 2014-09-03 | 2020-09-04 | Immunogen Inc | Derivados citotóxicos de benzodiazepina |
| JP2017529837A (ja) * | 2014-09-03 | 2017-10-12 | イミュノジェン・インコーポレーテッド | 細胞結合剤及び細胞毒性剤を含む複合体 |
| RS60305B1 (sr) | 2014-09-05 | 2020-07-31 | Janssen Pharmaceutica Nv | Agensi koji vezuju cd123 i njihove upotrebe |
| RU2733740C2 (ru) | 2015-06-29 | 2020-10-06 | Иммуноджен, Инк. | Конъюгаты сконструированных антител с цистеиновыми заменами |
| BR112017027254A2 (pt) | 2015-06-29 | 2019-05-14 | Immunogen, Inc. | anticorpos anti-cd123 e conjugados e derivados dos mesmos |
| DK3380525T3 (da) * | 2015-11-25 | 2024-01-29 | Immunogen Inc | Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf |
| US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
| TWI845890B (zh) * | 2016-11-23 | 2024-06-21 | 美商伊繆諾金公司 | 苯二氮平衍生物之選擇性磺化 |
| EP4374850A2 (en) * | 2017-09-22 | 2024-05-29 | ImmunoGen, Inc. | Methods of preventing methionine oxidation in immunoconjugates |
| TWI826393B (zh) * | 2017-09-22 | 2023-12-21 | 美商免疫遺傳股份有限公司 | 使用陽離子交換層析法分離三輕鏈抗體 |
| JP7474195B2 (ja) | 2018-01-12 | 2024-04-24 | イミュノジェン， インコーポレイテッド | 抗体薬物のコンジュゲーション、精製、及び製剤のための方法 |
-
2016
- 2016-06-28 BR BR112017027254-7A patent/BR112017027254A2/pt active Search and Examination
- 2016-06-28 US US15/195,401 patent/US10077313B2/en active Active
- 2016-06-28 SI SI201631099T patent/SI3313884T1/sl unknown
- 2016-06-28 AU AU2016285552A patent/AU2016285552B2/en active Active
- 2016-06-28 PL PL16736718T patent/PL3313884T3/pl unknown
- 2016-06-28 HR HRP20210263TT patent/HRP20210263T1/hr unknown
- 2016-06-28 CA CA2989321A patent/CA2989321A1/en active Pending
- 2016-06-28 WO PCT/US2016/039797 patent/WO2017004026A1/en not_active Ceased
- 2016-06-28 CN CN201680038058.2A patent/CN107889493B/zh active Active
- 2016-06-28 EP EP16736718.4A patent/EP3313884B9/en active Active
- 2016-06-28 RS RS20210197A patent/RS61452B9/sr unknown
- 2016-06-28 CN CN202210033457.7A patent/CN114671951A/zh active Pending
- 2016-06-28 EP EP20208057.8A patent/EP3842459A1/en active Pending
- 2016-06-28 PT PT167367184T patent/PT3313884T/pt unknown
- 2016-06-28 LT LTEP16736718.4T patent/LT3313884T/lt unknown
- 2016-06-28 RU RU2017146345A patent/RU2739612C2/ru active
- 2016-06-28 MD MDE20180449T patent/MD3313884T2/ro unknown
- 2016-06-28 KR KR1020187002732A patent/KR102663480B1/ko active Active
- 2016-06-28 DK DK16736718.4T patent/DK3313884T3/da active
- 2016-06-28 HU HUE16736718A patent/HUE053619T2/hu unknown
- 2016-06-28 CN CN202510430627.9A patent/CN120248124A/zh active Pending
- 2016-06-28 CN CN202210033558.4A patent/CN114672490A/zh active Pending
- 2016-06-28 SG SG10202005144TA patent/SG10202005144TA/en unknown
- 2016-06-28 KR KR1020247014500A patent/KR20240063203A/ko not_active Ceased
- 2016-06-28 ES ES16736718T patent/ES2887273T3/es active Active
- 2016-06-28 SM SM20210092T patent/SMT202100092T1/it unknown
- 2016-06-28 JP JP2017568261A patent/JP7203497B2/ja active Active
- 2016-06-29 AR ARP160101974A patent/AR105194A1/es unknown
- 2016-06-29 TW TW112134213A patent/TW202423981A/zh unknown
- 2016-06-29 TW TW105120515A patent/TWI727958B/zh active
- 2016-06-29 TW TW110114906A patent/TW202134284A/zh unknown
-
2017
- 2017-08-03 US US15/667,697 patent/US10919969B2/en active Active
- 2017-12-12 IL IL256271A patent/IL256271B/en unknown
-
2018
- 2018-04-19 US US15/957,757 patent/US10442865B2/en active Active
-
2020
- 2020-01-31 US US16/778,988 patent/US10875925B2/en active Active
- 2020-10-22 US US17/077,877 patent/US11332535B2/en active Active
- 2020-12-18 ZA ZA2020/07918A patent/ZA202007918B/en unknown
-
2021
- 2021-02-17 CY CY20211100133T patent/CY1123884T1/el unknown
- 2021-11-25 IL IL288391A patent/IL288391A/en unknown
-
2022
- 2022-04-01 US US17/711,518 patent/US11897961B2/en active Active
- 2022-12-23 AU AU2022291603A patent/AU2022291603A1/en active Pending
- 2022-12-27 JP JP2022209445A patent/JP7611218B2/ja active Active
-
2024
- 2024-12-23 JP JP2024226350A patent/JP2025041791A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018524349A5 (enExample) | ||
| RU2017146345A (ru) | Анти-cd123 антитела и их конъюгаты и производные | |
| US11584801B2 (en) | Anti-5T4 antibodies and antibody-drug conjugates | |
| US10912842B2 (en) | CD123 antibodies and conjugates thereof | |
| CN110240655B (zh) | 抗her2抗体及其缀合物 | |
| US11834498B2 (en) | Biparatopic FR-alpha antibodies and immunoconjugates | |
| ES2787180T3 (es) | Lanzaderas de transporte al cerebro de anticuerpos anti-tau(pS422) humanizados y uso de las mismas | |
| HK1221153A1 (zh) | 抗体-药物缀合物 | |
| JP2012522513A5 (enExample) | ||
| CN111110862A (zh) | 抗cldn18．2抗体的药物偶联体及其制备方法和用途 | |
| JP7726534B2 (ja) | 抗ｂ７ｈ４抗体及びその二重特異性抗体および用途 | |
| JP2014509835A5 (enExample) | ||
| IL305954A (en) | Nectin-4 protein antibody and extacan compounds | |
| JPWO2021213434A5 (enExample) | ||
| CN113906054A (zh) | 能够结合cd19和cd3的多特异性抗原结合蛋白及其用途 | |
| KR20220140786A (ko) | 클라우딘18.2 항체 및 그것의 사용 | |
| JPWO2020086665A5 (enExample) | ||
| CN114829405B (zh) | 抗bcma/抗4-1bb双特异性抗体及其用途 | |
| US20250066499A1 (en) | Antibody binding to human cd73, preparation method therefor, and use thereof | |
| US20250197501A1 (en) | Recombinant antibody, immunoconjugate comprising the same, and uses thereof in treating cancers | |
| CN120829509A (zh) | 抗ror1抗体、其免疫缀合物及其应用 | |
| RU2791445C2 (ru) | Новые анти-cd19-антитела | |
| WO2024067764A1 (zh) | 抗gpc3单克隆抗体/双特异性抗体或其抗原结合片段及其用途 | |
| JP2025529238A (ja) | 抗ｐｖｒｉｇ抗体及びその使用 | |
| CN116997356A (zh) | 抗alpp/alppl2抗体和抗体-药物缀合物 |